Colorectal cancer cells are unique in that they escape Fasmediated cell death in the presence of Fas ligand, and we recently reported that AMP-activated protein kinaserelated kinase 5 (ARK5) suppresses cell death signaling mediated by cell death receptor in Akt-dependent manner. In the current study, therefore, we examined whether ARK5 is involved in the escape from Fas-mediated cell death of colorectal cancer cells. Among 10 cell lines, ARK5 mRNA expression was observed in LoVo, SW480, and SW1116 cell lines. Interestingly, SW480 and SW1116 cell lines, but not LoVo cell line, showed expressions of both Fas ligand (FasL) and Fas mRNAs. SW620 cell line also showed FasL mRNA; however, Fas and ARK5 mRNAs were not detected. Furthermore, wellcoincided expression among ARK5, FasL, and Fas mRNAs was observed in tumor tissues from patients with colorectal cancer, suggesting the suppression of FasL/Fas system-induced cell death by ARK5 in colorectal cancer cell lines. Intensive cell death, which was dependent on the FasL/Fas system was encountered when ARK5 antisense RNA (ARK5/AS) was introduced into SW480 cells. FLIP was expressed in only ARK5 mRNA-expressing cell lines, and ARK5/AS induced FLIP cleavage in a caspase-6-dependent manner. Amino-acid sequence analysis of caspase-6 revealed two putative sites of phosphorylation by ARK5 at Ser 80 and Ser
Introduction
ARK5, which is the fifth member of the AMPK catalytic subunit family, is a tumor malignancy-associated factor at the downstream of Akt (Suzuki et al., 2003a) . ARK5 activation is directly regulated by phosphorylation at its Ser 600 , and the activated ARK5 induces cell survival during nutrient starvation and death receptor activation (Suzuki et al., 2003a, b) , and tumor cell invasion and metastasis . However, the precise mechansims of how ARK5 activity inhibits caspasedependent cell death remains to be determined.
Both cell death and cell survival are important for cellular homeostasis; therefore, an imbalance of their signaling causes several disease states, including tumorigenesis (Wyllie et al., 1980; Datta et al., 1999) . Recently, some factors have been identified as the key regulator promoting cell death and cell survival. Fas is the type I transmembrane protein mediating intracellular cell death signaling upon the stimulation of Fas ligand (FasL) (Nagata, 1997) . When Fas is activated by the ligation of FasL, an intracellular interaction of Fasdeath domain (Fas-DD), FADD, and caspase-8 (deathinducing signaling complex (DISC) recruitment) is initiated for the activation of executioner caspase (Nagata, 1997); and cellular FLIP (cFLIP) is well known as the inhibitor of DISC recruitment (Irmler et al., 1997; Thome et al., 1997) . As a result of mRNA splicing, there are two types in cFLIP protein: cFLIP long form contains both death-effector domain (DED) and caspase-like domain, and only DED is contained in short form of cFLIP (cFLIPs) (Irmler et al., 1997) . In contrast, Akt which is a serine/threonine protein kinase induces cell survival as a result of phosphorylation and several cell death-associated factors, such as Bad (Datta et al., 1997; Peso et al., 1997) , caspase-9 (Cardone et al., 1998) and Forkhead , upon the stimulation of growth factor receptor and integrin-induced cell signaling (Datta et al., 1999; Brazil et al., 2002) . Furthermore, we recently demonstrated that members of AMPK catalytic subunit family play a major role in tumor cell survival during nutrient starvation and tumorigenesis (Izuishi et al., 2000; Esumi et al., 2002; Hashimoto et al., 2002; Kato et al., 2002) .
Colorectal cancer is one of the leading causes of death by cancer in developed countries (Berman et al., 2001; Nakanishi et al., 2002) . ARK5 expression was well observed in tumor cells (Suzuki et al., 2003a) , and we recently demonstrated that colorectal cancer tissues from patients showed specific expression of ARK5 mRNA in a stage-dependent manner , suggesting close involvement of ARK5 in colorectal carcinogenesis and its progression. In addition, FasL/Fas system has been reported to be involved in colorectal cancer progression (Shiraki et al., 1997; Ding et al., 1998; O'Connell et al., 1998; Peudo-Eberl et al., 1999; Bennett et al., 2001) . Although Fas expression was observed in both normal and tumor cells of the colon (Watanabe-Fukunaga et al., 1992; Leithauser et al., 1993) , FasL expression was specifically induced in colorectal cancer cells at an early stage during carcinogenesis (Bennett et al., 2001 ) and expressed FasL was reported to be important in immune evasion of tumor cells and liver metastasis (Shiraki et al., 1997; O'Connell et al., 1998) . These hypotheses are very interesting, but how colorectal cancer cells themselves do not undergo cell death even in the presence of both FasL and Fas on their cell surface remains to be elucidated. In this study, we examined the mechanism for this paradox and found ARK5 to be one of the mechanisms.
Results and discussion
Colorectal cancer is one of the leading causes of cancer death in developed countries, and many investigations to clarify the molecular mechanism of colorectal carcinogenesis have been extensively progressed (Berman et al., 2001; Nakanishi et al., 2002) . ARK5, which is the member of AMPK leading tumor cell survival at the downstream of Akt, is closely involved in tumor progression (Suzuki et al., 2003a (Suzuki et al., , b, 2004 . Recently, we demonstrated that ARK5 mRNA was specifically observed in colorectal cancer tissues but not in colorectal nontumor tissues , suggesting that ARK5 expression is involved in colorectal carcinogenesis. In addition, it has been reported that an expression of FasL is also induced specifically in colorectal cancer tissues from an earlier stage during carcinogenesis (Bennett et al., 2001 ) and has been hypothesized that the newly expressed FasL is involved in immune evasion of tumor cells and liver metastasis (Shiraki et al., 1997; Ding et al., 1998; O'Connell et al., 1998; Peudo-Eberl et al., 1999; Bennett et al., 2001 ). In the current study, FasL mRNA expression was observed in three cell lines (SW480, SW620, and SW1116 cell lines) within 10 human colorectal cancer cell lines (Figure 1 ). Interestingly, both SW480 and SW1116 cell lines, in which Fas mRNA expression was also detected, showed ARK5 mRNA expression (Figure 1 ). In contrast, Fas mRNA-unexpressing SW620 cell line did not show ARK5 mRNA expression (Figure 1 ). Although LoVo cell line showed ARK5 mRNA expression, either FasL or Fas mRNA expression was not detected (Figure 1) . Furthermore, expressions of ARK5 and FasL mRNAs were observed in surgically resected colorectal cancer tissues at stage Dukes' C, but not in normal colorectal epithelial tissues, and Fas mRNA expression was observed in all tissues (Figure 1 ). All the cell lines and clinical samples that expressed FasL mRNA were found to express ARK5 mRNA, indicating that ARK5 might be involved in protecting cancer cells from FasL-dependent cell death.
To examine the role of ARK5 in both FasL-and Fasexpressing human colorectal cancer cells, we prepared antisense RNA expression vector (ARK5/AS) and RNAi (ARK5i) of ARK5. The transfection efficiency of SW1116 cells (0.8%) was very low as compared with SW480 cells (98.6%) (data not shown). Therefore, we used only SW480 cells for the following experiments. As shown in Figure 2a , an introduction of ARK5/AS or ARK5i induced a dramatic decrease in an expression of ARK5 at the protein level. In contrast, both ARK5/AS and ARK5i did not influence expressions of AMPK-a or actin (Figure 2a) , indicating the specificities of ARK5/ AS and ARK5i. In addition, we also examined expression status of transiently expressed dominantnegative-ARK5 (DN-ARK5) and dominant-negativeAkt1 (DN-Akt)1 in both SW480 and DLD-1 cell lines. They were efficiently expressed (Figure 2b ). ARK5 belongs to the AMPK catalytic subunit family (Suzuki et al., 2003a) ; therefore, we also examined the efficacy of antisense RNA expression vector of AMPK-a1 (AMPK-a1/AS and Esumi et al., 2002; Kato et al., 2002) . As shown in Figure 2c , an introduction of AMPK-a1/AS into SW480 cells showed a dramatic To examine whether ARK5 promotes cell survival against Fas-mediated cell death, the effect of ARK5 overexpression was investigated. Among ARK5 mRNA-unexpressing cell lines, DLD-1, HCT-15, HCT-116, and WiDr cell lines were suitable for gene transfection experiments; therefore, cells were transfected with ARK5 expression vector and exposed to agonistic Fas antibody (CH-11 clone) in the presence of actinomycin D. Although all cell lines showed an extensive cell death within 24 h when cells were exposed to Fas antibody and actinomycin D (Figure 3a) , the remarkable protection was caused by ARK5 overexpression ( Figure 3a) . Furthermore, LoVo cell line in which ARK5 and Fas mRNA, but not Fas L mRNA, were expressed, was transfected with ARK5/AS, and then cells were exposed to agonistic Fas antibody in the presence and absence of actinomycin D. As shown in Figure 3b , for LoVo cell line, both parental and empty expression vector-transfected cells, did not show Fasmediated cell death within 24 h in the absence of actinomycin D. However, ARK5/AS-transfected LoVo cells showed a Fas-mediated cell death (about 50% cell death) even in the absence of actinomycin D (Figure 3b) , and more extensive cell death was triggered by Fas antibody stimulation in the presence of actinomycin D in ARK5/AS-transfected LoVo cells (Figure 3b ). In contrast, ARK5 was found to protect cells from Fasmediated cell death at the downstream of Akt signaling in DLD-1 cells. As shown in Figure 3c , Fas-mediated cell death was observed in DLD-1 cells in the presence of actinomycin D, and it was suppressed by ARK5 overexpression and accelerated by inhibition of Akt/ ARK5 system with ARK5/AS, DN-ARK5, DN-Akt1, or LY294002. Next, we examined an effect of ARK5/AS in SW480 cell line to investigate whether ARK5 promotes cell survival in cells expressing both Fas L and Fas on cell surface. As shown in Figure 4a , cell death was induced only in SW480 cells when ARK5/AS, ARK5i, DN-ARK5, and DN-Akt1 were introduced in the cells and LY294002 was added to medium ( Figure 4a ). In contrast, AMPK-a1/AS did not induce cell death in DLD-1 and SW480 cell lines (Figure 4a ). In addition, cell death induced by ARK5/AS in SW480 cells was dose dependent (Figure 4b ). Although both ARK5/AS and ARK5i dramatically suppressed ARK5 expression, especially ARK5i, which completely suppressed it, cell death caused by ARK5i (about 60% cell death induction) was smaller than that by ARK5/AS (about 80% cell death induction) ( Figure 4a ). Since empty vector or control RNAi did not affect cell viability, we thought that the effects of RNAi and antisense are specific. Recently, an induction of interferon signaling caused by an introduction of RNAi was In all, 1 mg DN-ARK5, DN-Akt1, or empty vector ( rt: À) was introduced into SW480 or DLD-1 cell line, and then expression of each dominant-negative form was examined by Western blotting using the antibody recognizing N-terminal tag protein (FLAG for DN-ARK5; myc for DN-Akt1). Cell extracts were also blotted by the antibody against actin (Actin). (c) In all, 1 mg expression vector containing or not containing (Empty) AMPK-a1/AS (a1/AS) was introduced into SW480 cells, and then extracted proteins were detected with the antibody against, AMPK-a1, AMPK-a2, or actin (Actin) Molecular mechanism of ARK5-induced tumor cell survival A Suzuki et al reported (Sledz et al., 2003) , and it has well known that interferon signaling modulates Fas-mediated cell death (Watanabe-Fukunaga et al., 1992; Leithauser et al., 1993; Liu and Abrams 2003) . Actually, ARK5i and control RNAi, but not ARK5/AS, induced a new expression of IFN-g mRNA in SW480 cells (data not shown). It is possible to speculate that the effect of ARK5i on cell death might be counteracted by interferon action. Since ARK5/AS also showed a specific decrease in ARK5 expression in SW480 cells, we used ARK5/AS for further experiments. Interestingly, the cell death induced by ARK5/AS was markedly suppressed when the cells were pretreated with neutralizing antibody against Fas (Figure 4c ). Our results strongly suggest that ARK5 suppresses the cell death signaling initiated by Fas activation at the downstream of Akt1.
The results of this study clearly demonstrated that ARK5 endogenously suppresses the FasL/Fas system in colorectal cancer cells expressing both FasL and Fas on their cell surface such as the SW480 cell line. To investigate the mechanism of this inhibition in greater detail, we examined caspases and related factors. Since our previous study showed that caspase-8 activation is inhibited by the action of ARK5 during cell death induced by glucose starvation (Suzuki et al., 2003b) , in the present study, we first investigated the expression of caspase-8, FADD, which is the adapter molecule interacting with Fas and caspase-8 (Chinnaiyan et al., 1995) , and the caspase-8 inhibitor cFLIP (Irmler et al., 1997) . As shown in Figure 5a , Western blotting analysis revealed cFLIPs expression only in ARK5-expressing cell lines, SW480 and SW1116 cell lines, suggesting a possible link between ARK5-mediated inhibition of cell death and cFLIPs. We also examined expressions of other antiapoptotic factors, Bcl-2, Bcl-xL, XIAP, and survivin; however, correlative expression with ARK5 was not observed (data not shown). In addition, introduction of ARK5/AS induced cFLIPs cleavage in a dose-dependent manner (Figure 5b ). Since caspase-dependent cleavage of cFLIPs is well known (Kelly et al., 2002; Kim et al., 2002) , we attempted to determine whether the amino-acid sequence of caspases 1-10 contains any putative ARK5 phosphorylation site (Hardie et al., 1998; Suzuki et al., 2003a) , and as shown in Figure 5c , only caspase-6 was found to have two putative ARK5 (AMPK) phosphorylation sites (Hardie and Carling 1997; Hardie et al., 1998; Suzuki et al., 2003a, b) . To date, three processes have been reported as mechanisms for loss of cFLIP: (1) proteolysis by caspase, as described above, (2) downregulation at the transcription level as a result of NF-kB inactivation (Kim et al., 2002) , and (3) ubiquitininduced degradation (Kim et al., 2002) . The second possibility is less likely, because ARK5 does not induce NF-kB activation (our unpublished data). The effect of MG-132, which is a well-known inhibitor of ubiquitininduced protein degradation, a broad inhibitor of caspase zVAD.fmk (zVAD), and a caspase-6 antisense RNA expression vector (caspase-6/AS), was investigated in ARK5/AS-induced cleavage of cFLIPs. As shown in Figure 5d , the ARK5/AS-induced cleavage of cFLIPs was clearly suppressed by zVAD and caspase-6/AS, but not by MG-132, suggesting that the ARK5/ AS-induced cleavage of cFLIPs is attributable to caspase-6. The interaction between ARK5 and caspase-6 was examined in more detail to elucidate the mechanism of cFLIPs stabilization. As shown in Figure 6a , caspase-6 was endogenously phosphorylated in SW480 cells and the phosphorylation decreased at 24 h, coinciding with the decrease in ARK5 expression induced by ARK5/AS introduction. These suggest a causal relationship between caspase-6 phosphorylation and ARK5 in SW480 cells. Since, as shown in Figure 5c , caspase-6 contains two putative phosphorylation sites, at Ser 80 (in the active domain) and Ser 257 (in the nonactive domain), we constructed expression vectors containing only the active domain of caspase-6 and full-length procaspase-6 and examined their expression (Figure 6b ). When procaspase-6 was expressed, DLD-1 cells underwent extensive cell death in a dose-dependent manner, but only limited cell death was observed in SW480 cells. In contrast, when active caspase-6 was introduced into the cell lines, cell death was observed equally in both the SW480 and DLD-1 cells (Figure 6c) . Moreover, the cell death induced by procaspase-6 overexpression was similarly suppressed by the overexpression of ARK5 in DLD-1 (D/ARK) cells (Figure 6d) , and procaspase-6 did not induce cell death in the presence of ARK5. These results suggest that ARK5 phosphorylates caspase-6 at Ser To test directly the possibility that ARK5 phosphorylates caspase-6 at Ser 257 , we prepared a mutant caspase-6 in which the 257th serine residue was substituted by alanine (caspase-6/SA) and Escherichia coli expression vector of the maltose-binding protein (MBP)-tagged ARK5 catalytic domain (ARK5/CD) in the current study. As shown in Figure 7a , ARK5/CD was phosphorylated in vitro by IGF-1-treated cell extracts and stimulated GST-SAMS phosphorylation activity, suggesting that ARK5/CD stimulated with IGF-1-treated cell extracts is enzymatically active. Using this active ARK5 (ARK5/CD), we examined whether caspase-6 is phosphorylated in vitro. As seen in Figure 7b , active ARK5 phosphorylated wild-type (wt) caspase-6 within 5 min and an extensive phosphorylation was observed at 30-60 min. In contrast, caspase-6/SA was not phosphorylated even in the presence of active ARK5 (Figure 7b ), suggesting that ARK5 phosphorylates caspase-6 at Ser 257 . To examine the biological significance of the caspase-6 phosphorylation by ARK5, we investigated the effect of caspase-6/SA mutant on the induction of cell death and cFLIPs cleavage. DLD-1 cells underwent cell death in response to both types of caspase-6; however, SW480 and D/ARK cells, which showed strong resistance to wt-caspase-6, exhibited cell death in the presence of caspase-6/SA (Figure 7c ). In addition, the cFLIPs cleavage triggered by ARK5/AS, as described above, was induced by caspase-6/SA in a dose-dependent manner, but not by wt caspase-6 (Figure 7d ). Our results strongly suggest that ARK5 phosphorylates caspase-6, and the phosphorylation seems to induce the suppression of caspase-6 activation. To examine directly whether ARK5 suppresses caspase-6 activation, in vitro caspase-6 activity was tested. As shown in Figure 7e , recombinant active caspase-6 showed a caspase-6 activity (VEID-pNA cleavage activity). Wt caspase-6 (full length: collected from transfected cells) showed a slight activity and a dramatically increased activity was observed when wild-type capase-6 was treated with recombinant active caspase-3 (Figure 7e ). Since the recombinant active caspase-3 treated with Ac-DEVD-CHO, an inhibitor of caspase-3 (FernandesAlnemri et al., 1994; Thornbery et al., 1997), did not induce caspase-6 activation (Figure 7e ), in vitro caspase-6 activation is regulated by caspase-3. Interestingly, active ARK5-treated wild-type caspase-6 showed very weak activity even in the presence of active caspase-3; however, active ARK5-treated caspase-6/SA showed an intense activity in the presence of active caspase-3. These results strongly suggest that the suppression of caspase-6 activation by caspase-3 is caused by phosphorylation. We report here that ARK5 phosphorylates caspase-6 at Ser 257 , leading to inactivation of caspase-6 and resulting in resistance to cell death via cFLIPs protection.
Through the current investigation to clarify the role of ARK5 in colorectal cancer cells, we demonstrated that ARK5 directly inactivates caspase-6 through the phosphorylation at Ser 257 , resulting in cFLIPs preservation, which in turn suppresses caspase-8 activation that otherwise would occur as a result of expression of both Fas and FasL in the same cell. FasL has been reported to be newly expressed in cancer cells during carcinogenesis (Shiraki et al., 1997; Ding et al., 1998; O'Connell et al., 1998; Peudo-Eberl et al., 1999; Bennett et al., 2001 ), and we also observed both FasL and Fas mRNAs expression in cancer (cell lines and clinical samples). Human colorectal cancer cell lines SW480 and SW1116 are colorectal cancer cells expressing both the cell death receptor Fas and its ligand factor FasL on the cell surface, and thus these cells may undergo apoptotic cell death unless some safeguard is generated endogenously. The role of FasL expressing in colorectal cancer cells has been proposed as 'immune evasion (O'Connell et al., 1998)' and 'liver metastasis (Shiraki et al., 1997) '. In either case, FasL seems to be important for colorectal carcinogenesis, since its expression is newly induced at an earlier stage during carcinogenesis. Our results strongly suggest that ARK5 plays an important role in colorectal carcinogenesis through the protection of the FasL-expressing colorectal cancer cells. In addition, we have demonstrated that tumor invasion and metastasis are accelerated by ARK5 expression in an animal model . ARK5 may therefore be an important target of colorectal cancer from both a diagnostic and therapeutic viewpoint. 32 P-incorporated MBP-ARK5/CD was cleaved with Tev protease to produce tag-free ARK5/CD, and then 32 Pincorporated free MBP-ARK5/CD was mixed with GST-SAMS. 32 P-incorporation into GST-SAMS (pSAMS) was detected by autoradiography. Each tagged protein were also detected by Western blotting using anti-MBP tag (tMA5) and anti-GST tag (tSAMS) antibodies. (b) In all, 1 mg FLAG-tagged caspase-6 (wt: Cas-6/WT; caspase-6/SA: Cas-6/SA) was incubated with above 32 Pincorporated MBP tagfree ARK5/CD, and 32 P incorporation into caspase was assessed by autoradiography (pCas-6). Caspase-6 protein was detected with Western blotting (tCas-6). Wt caspase-6 (wtCas-6) and SA-mutated caspase-6 (mtCas-6 (SA)) treated with or without active ARK5/CD were reacted with active caspase-3 (ActCas-3 (r)). After the reaction, caspase-6 activity was measured using its colorimetric assay kit. In the current study, active caspase-6 (ActCas-6 (r)) was used as the control
Materials and methods

Cell line, culture, and transfection
In all, 10 human colorectal cancer cell lines COLO201, DLD-1, HCT-15, HCT-116, LoVo, LS1034, SW480, SW620, SW1116, and WiDr were purchased from ATCC and maintained in Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum (Sigma Chemical Co, Ltd, St Louis, MO, USA). For transfection, cells were seeded into a 24-well plate at 5 Â 10 4 /well, and transfection was performed by using TransFast Transfection Reagent (Promega Corp., Madison, WI, USA) with some modification; plasmid/TransFast Reagent mixture was exposed to cells for 4 h. The transfection yield was assessed with green fluorescence protein, and the yield in the current study was 98% in the DLD-1 cell line, 97.2% in the WiDr cell line, 98.6% in the SW480 cell line, and 0.8% in the SW1116 cell line.
Tissue sampling
Normal and tumor tissues (three cases of primary foci at Dukes' C and three of liver metastasis) were obtained from the surgical specimens of cancer patients who had undergone surgical resection in the National Cancer Center Hospital East. The tissues were collected at the time of surgery and immediately stored in liquid nitrogen until they were used for RNA extraction. All tissue samples were collected after obtaining informed consent.
Antibody, recombinant protein, and vector
Neutralizing antibody against human Fas (ZB4 clone) was purchased from the Medical and Biological Laboratory (MBL: Nagoya, Japan). The Fc-chimera proteins of TNF-R1, TRAIL-R2 (Alexis Corp., Lausen, Switzerland), and TRAIL-R1 (Dako Japan Co, Ltd, Kyoto, Tokyo) were purchased. DN-Akt1 and antibody against human caspase-8, FLIP, or caspase-6 were purchased from Upstate Biotechnology (Charlottesville, VA, USA). Anti-FADD antibody was purchased from Transduction Laboratory (Lexington, KY, USA). ARK5/AS (Suzuki et al., 2003a, b) , DN-ARK5, which was prepared by conversion of the Akt-phosphorylating serine residue (Ser600) to an alanine residue (Suzuki et al., 2003a , and AMPK-a1/AS Kato et al., 2002) were used for the experiment in the same manner as reported previously.
FLAG-tagged caspase-6, procaspase-6, active caspase-6, and caspase-6/AS were cloned by polymerase chain reaction (PCR) technology using first-strand cDNA prepared from SW480 cells. Each PCR product was subcloned using TOPO-TA cloning pCR2.1 vector. The plasmids were digested by EcoR1 and Xho1 after sequencing, and religated into pcDNA3.1( þ ) expression vector.
Mutagenesis of caspase-6 (S257A) for preparation of caspase-6/SA was performed by the PCR method using the mutagenesis primers (SA mutant primer-1: 5 0 -TCGGCGCT GGGCAACTTTCCT-3 0 ; and SA mutant primer-2: 5 0 -AG-GAAAGTTGCCCAGCGCCGA-3 0 ). PCR was performed using SA mutant primer-1 and T7 promoter primer on pcDNA3.1( þ ), and SA mutant primer-2 and pcDNA3.1/ BGH reverse primer on pcDNA3.1( þ ). Each PCR product was electrophoresed on 1% agarose gel and extracted from gel using Wizard SV Gel PCR Clean-Up System (Promega). Both PCR products were mixed, annealed, amplified by full-length caspase-6 amplify primer, and subcloned into TOPO-TA cloning pCR2.1 vector. After sequencing, mutated caspase-6 was ligated into pcDNA3.1( þ ).
MBP-ARK5/CD, in which Tev protease site was contained was prepared by generating PCR product with ARK5 cDNA as a template, and then subcloned with TOPO-TA cloning pCR2.1 vector. After sequencing, the plasmid was digested with EcoR1 and Sal1, ligated into pMal-c2X (New England Biolabs Inc., Beverly, MA, USA), and transformed into pBL21(DE3)GC-rich version E. coli. MBP-ARK5/CD was purified with amylose resin and the recombinant protein was eluted by maltose.
Recombinant proteins of active caspase-3 and -6 were purchased from MBL, and caspase-6 colorimetric assay kit was also purchased from MBL. The caspase-6 activity assay was performed using the instruction manual.
RNAi preparation
RNAi for ARK5 was prepared using HiScribe RNAi Transcription Kit purchased from New England BioLabs Inc. (Beverly, MA, USA). An ARK5 cDNA fragment (2022-2281) was prepared by PCR with full-length ARK5 cDNA as the template, and the PCR product was subcloned by ligating into pCR2.1-Topo vector (Invitrogen BV, Groningen, The Netherlands). The ARK5 fragment-inserted vector was digested by BamH1 and Xho1 and religated into 28i-pLITMUS RNAi vector. The RNAi was prepared by in vitro transcription with T7 RNA polymerase. The efficacy of the RNAi was studied by disappearance of ARK5 protein during the Western blotting procedure. As the control of RNAi, double-stranded RNA, which was prepared by the in vitro transcription of empty 28i-pLITMUS RNAi vector, was used as recommended in the instruction manual.
RNA extraction and reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA extraction from cell lines and tissue samples was performed with ISOGEN (Wako Pure Chemical Co, Ltd, Osaka, Japan) for RT-PCR.
Extracted RNA (100 ng) was reverse transcribed to firststrand cDNA using AMV-reverse transcriptase (Takara Biochemicals, Kyoto, Japan) and oligo-dT16 primer, and then PCR was performed with LA PCR Kit Ver. 2.1 (Takara Biochemicals).
Cell survival assay
Cell viability was assessed by the Hoechst 33342/PI staining procedure. Hoechst 33342 and PI were purchased from Molecular Probes Inc. (Eugene, OR, USA). After incubation, cells were collected and stained with Hoechst 33342 and PI, and then examined by fluorescence microscopy. The cell death induction ratio was calculated as the ratio of cells containing cell death nuclei to the total number of cells (approximately 500 cells).
Western blotting
Proteins were prepared for Western blotting analysis by lysing cells for 30 min with 1% NP-40 containing PBS. All procedures were carried out at 41C. Supernatants were collected by centrifugation at 15 000 r.p.m. for 15 min, and their protein concentrations were determined with a BCA protein assay kit (Pierce) with bovine serum albumin as a standard. Sample proteins separated by SDS-PAGE were transferred onto nitrocellulose membranes by a semi-dry blotting system. The membranes were blocked at room temperature for 1 h with PBS containing 5% (w/v) skim milk, washed with a mixture of PBS and 0.05% Tween 20 (Sigma, Tween-PBS), and then incubated overnight at room temperature with antibody diluted with PBS. 
